Literature DB >> 4378402

Protein binding of diphenylhydantoin and desmethylimipramine in plasma from patients with poor renal function.

M M Reidenberg, I Odar-Cederlöf, C von Bahr, O Borgå, F Sjöqvist.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1971        PMID: 4378402     DOI: 10.1056/NEJM197107292850506

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  85 in total

1.  The value of serum diphenylhydantoin (phenytoin) levels in the management of epilepsy.

Authors:  E H Reynolds
Journal:  Proc R Soc Med       Date:  1975-02

Review 2.  Disease-induced variations in plasma protein levels. Implications for drug dosage regimens (Part II).

Authors:  R Zini; P Riant; J Barré; J P Tillement
Journal:  Clin Pharmacokinet       Date:  1990-09       Impact factor: 6.447

3.  Plasma protein binding of phenylbutazone during recovery from acute renal failure.

Authors:  M M Mussche; F M Belpaire; M G Bogaert
Journal:  Eur J Clin Pharmacol       Date:  1975-10-10       Impact factor: 2.953

4.  Pharmacokinetics of drugs in patients with the nephrotic syndrome.

Authors:  R Gugler; D W Shoeman; D H Huffman; J B Cohlmia; D L Azarnoff
Journal:  J Clin Invest       Date:  1975-06       Impact factor: 14.808

5.  Two-fold interindividual variation in plasma protein binding of phenytoin in patients with epilepsy.

Authors:  N Barth; G Alván; O Borgå; F Sjöqvist
Journal:  Clin Pharmacokinet       Date:  1976 Nov-Dec       Impact factor: 6.447

6.  Propranolol disposition in renal failure.

Authors:  A J Wood; R E Vestal; C L Spannuth; W J Stone; G R Wilkinson; D G Shand
Journal:  Br J Clin Pharmacol       Date:  1980-12       Impact factor: 4.335

Review 7.  Pharmacokinetics and response to diazoxide in renal failure.

Authors:  R M Pearson
Journal:  Clin Pharmacokinet       Date:  1977 May-Jun       Impact factor: 6.447

8.  Plasma protein binding of perazine and amitriptyline in psychiatric patients.

Authors:  M Brinkschulte; H J Gaertner; H W Schied; U Breyer-Pfaff
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

9.  Plasma protein binding of azapropazone in patients with kidney and liver disease.

Authors:  E Jähnchen; K J Blanck; K H Breuing; H J Gilfrich; T Meinertz; D Trenk
Journal:  Br J Clin Pharmacol       Date:  1981-04       Impact factor: 4.335

10.  Renal function, protein binding and pharmacological response to diazoxide.

Authors:  R M Pearson; A M Breckenridge
Journal:  Br J Clin Pharmacol       Date:  1976-02       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.